Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the androgen receptor inhibitor ODM-201, which is used to treat castration-resistant prostate cancer.
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the androgen receptor inhibitor ODM-201, which is under investigation as a treatment for men with castration-resistant prostate cancer (CRPC).
A series of phase I and II multinational trials have studied the efficacy of ODM-201 in CRPC, Shore notes. So far, great results have been demonstrated in terms of modulation of PSA kinetics. In addition to ODM-201's efficacy, researchers are also looking at the drug’s unique organic structure, which seems to cause the agent to have a much lower penetration through the blood-brain barrier.
Clinical trials thus far have carefully monitored the tolerability and performance of ODM-201 in CRPC, Shore notes. Additionally, the drug’s efficacy impact is also being measured, in terms of radiographic disease, PSA, and the impact on the androgen receptor.
At this point, OBM-201 has been explored in a number of settings for patients with CRPC, including prior to chemotherapy before the administration of abiraterone, following treatment with abiraterone, and in patients who have received chemotherapy.